Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Denny

Showing results (61-70 of 748) with videos related to

Pageof 75
Sort By:
Anti-Cancer Drug Design|May 1, 1990
Kinetics of the binding of mitoxantrone, ametantrone and analogues to DNA: relationship with binding mode and anti-tumour activityW A Denny, L P Wakelin
Journal of Medicinal Chemistry|June 1, 1986
Considerations for the design of nitrophenyl mustards as agents with selective toxicity for hypoxic tumor cellsW A Denny, W R Wilson
Journal of Medicinal Chemistry|April 1, 1977
Potential antitumor agents. 21. Dialkanolamine dialkanesulfonic estersB F Cain, W A Denny
Expert Opinion on Therapeutic Patents|October 28, 2020
Small-molecule CSF1R kinase inhibitors; review of patents 2015-presentWilliam A Denny, Jack U Flanagan
The Journal of Nursing Education|January 1, 1979
A comparison of mental health nursing education in the United Kingdom and the psychiatric component of a baccalaureate program in the United StatesE O Denny, J A Denny
Future Medicinal Chemistry|March 24, 2011
The nitroimidazooxazines (PA-824 and analogs): structure-activity relationship and mechanistic studiesWilliam A Denny, Brian D Palmer
Best Practice & Research. Clinical Obstetrics & Gynaecology|September 10, 2005
Human papillomavirus testing and screeningL A Denny, T C Wright
The Anatomical Record|March 30, 1999
Dynamics of parenchymal cell division, differentiation, and apoptosis in the young adult female mouse submandibular glandP C Denny, P A Denny
Expert Opinion on Investigational Drugs|November 28, 2000
Tirapazamine: a bioreductive anticancer drug that exploits tumour hypoxiaW A Denny, W R Wilson
Mutation Research|September 1, 1995
Anticancer drugs: an underestimated risk or an underutilised resource in mutagenesis?L R Ferguson, W A Denny
Pageof 75

Showing results (61-70 of 748) with videos related to

Sort By:
Pageof 75
Anti-Cancer Drug Design|May 1, 1990
Kinetics of the binding of mitoxantrone, ametantrone and analogues to DNA: relationship with binding mode and anti-tumour activityW A Denny, L P Wakelin
Journal of Medicinal Chemistry|June 1, 1986
Considerations for the design of nitrophenyl mustards as agents with selective toxicity for hypoxic tumor cellsW A Denny, W R Wilson
Journal of Medicinal Chemistry|April 1, 1977
Potential antitumor agents. 21. Dialkanolamine dialkanesulfonic estersB F Cain, W A Denny
Expert Opinion on Therapeutic Patents|October 28, 2020
Small-molecule CSF1R kinase inhibitors; review of patents 2015-presentWilliam A Denny, Jack U Flanagan
The Journal of Nursing Education|January 1, 1979
A comparison of mental health nursing education in the United Kingdom and the psychiatric component of a baccalaureate program in the United StatesE O Denny, J A Denny
Future Medicinal Chemistry|March 24, 2011
The nitroimidazooxazines (PA-824 and analogs): structure-activity relationship and mechanistic studiesWilliam A Denny, Brian D Palmer
Best Practice & Research. Clinical Obstetrics & Gynaecology|September 10, 2005
Human papillomavirus testing and screeningL A Denny, T C Wright
The Anatomical Record|March 30, 1999
Dynamics of parenchymal cell division, differentiation, and apoptosis in the young adult female mouse submandibular glandP C Denny, P A Denny
Expert Opinion on Investigational Drugs|November 28, 2000
Tirapazamine: a bioreductive anticancer drug that exploits tumour hypoxiaW A Denny, W R Wilson
Mutation Research|September 1, 1995
Anticancer drugs: an underestimated risk or an underutilised resource in mutagenesis?L R Ferguson, W A Denny
Pageof 75